Onco-Innovations Advances PNKP Inhibitor Development with Nucro-Technics' Bioanalysis

Onco-Innovations Limited has initiated a key phase in its PNKP Inhibitor Technology development. Nucro-Technics Inc., a Toronto-based contract research organization, has begun advanced bioanalytical work in support of Onco's non-GLP pharmacokinetic and biodistribution animal model study. This work focuses on the active pharmaceutical ingredient A83B4C63.

The specialized LC-MS analytical methods developed by Nucro-Technics are crucial for measuring the API within biological samples. These methods enable a deeper understanding of how the compound behaves in vivo, contributing valuable insights into its exposure and distribution.

This analytical phase reinforces Onco's preclinical program, aiding in refining dosing strategies and informing formulation work. The efforts are in line with Onco's broader goal to advance its PNKP Inhibitor Technology toward clinical evaluation.